Personalizing Prostate Cancer Screening May Improve Detection Accuracy
The accuracy of PSA in prostate cancer screening can be improved by accounting for genetic factors that are not associated with cancer.
The accuracy of PSA in prostate cancer screening can be improved by accounting for genetic factors that are not associated with cancer.
Cleveland Diagnostics announced an agreement with Quest Diagnostics to expand patient access to its novel prostate cancer test, IsoPSA.
Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer.
A new study investigated genomic biomarkers associated with aggressive disease in African American men with prostate cancer.
Read MoreMen at the highest risk for prostate cancer could be fast-tracked for investigation if their genetic risk was considered in general practice.
Read MoremiR Sentinel is a novel, urine-based molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm.
Read MoreNanostics’ ClarityDX Prostate test is designed to improve the accuracy of detecting significant prostate cancer in men at risk of the disease.
Read MoreThe incidence of more aggressive prostate cancer cases that are higher-grade disease and metastasis at diagnosis have risen.
Read MorePSA screening for prostate cancer could be improved by accounting for genetic factors that cause PSA changes not associated with cancer.
Read MoreDigital pathology solutions provider Lumea and Verily, an Alphabet a precision health company,...
Read MoreThe incidence rate of metastatic prostate cancer increased for men 45 and older and coincides with recommendations against screenings.
Read MoreResearchers have developed a semiconductor sensor capable of detecting ultra-low concentrations of tumor markers, on chips made using micromachine tech.
Read MoreThe FDA has granted Breakthrough Device Designation for Datar Cancer Genetics’ TriNetra-Prostate blood test to detect early-stage prostate cancer.
Read MoreA senior medical director for Quest Diagnostics discusses how the pandemic impacted prostate cancer diagnostics and how it will impact clinical labs.
Read MoreA portable and rapid prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer.
Read MoreA new study has identified novel cancer markers in patients with aggressive prostate cancer that indicate poorer survival.
Read MoreExact Sciences has announced results underscoring the importance of adverse pathology as a reliable and critical endpoint for prostate cancer patients.
Read MoreIn a large study, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions by the USPSTF on screening.
Read More